DE602007012743D1 - Verwendung eines antikörpers gegen cd151 bei der behandlung von primären krebs - Google Patents

Verwendung eines antikörpers gegen cd151 bei der behandlung von primären krebs

Info

Publication number
DE602007012743D1
DE602007012743D1 DE602007012743T DE602007012743T DE602007012743D1 DE 602007012743 D1 DE602007012743 D1 DE 602007012743D1 DE 602007012743 T DE602007012743 T DE 602007012743T DE 602007012743 T DE602007012743 T DE 602007012743T DE 602007012743 D1 DE602007012743 D1 DE 602007012743D1
Authority
DE
Germany
Prior art keywords
treatment
protein
antibody against
primary cancer
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007012743T
Other languages
English (en)
Inventor
Jean-Francois Haeuw
Liliane Goetsch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37866318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602007012743(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Publication of DE602007012743D1 publication Critical patent/DE602007012743D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE602007012743T 2006-10-18 2007-10-15 Verwendung eines antikörpers gegen cd151 bei der behandlung von primären krebs Active DE602007012743D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0609135A FR2907341B1 (fr) 2006-10-18 2006-10-18 Utilisation d'un anticorps anti-cd151 pour le traitement du cancer
PCT/FR2007/001688 WO2008049990A2 (fr) 2006-10-18 2007-10-15 Utilisation d'un anticorps anti-cd151 pour le traitement du cancer

Publications (1)

Publication Number Publication Date
DE602007012743D1 true DE602007012743D1 (de) 2011-04-07

Family

ID=37866318

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007012743T Active DE602007012743D1 (de) 2006-10-18 2007-10-15 Verwendung eines antikörpers gegen cd151 bei der behandlung von primären krebs

Country Status (28)

Country Link
US (2) US8178096B2 (de)
EP (1) EP2079482B1 (de)
JP (2) JP5757646B2 (de)
KR (1) KR101521863B1 (de)
CN (1) CN101528256B (de)
AT (1) ATE499387T1 (de)
AU (1) AU2007310763B2 (de)
BR (1) BRPI0717455A2 (de)
CA (1) CA2665912C (de)
DE (1) DE602007012743D1 (de)
DK (1) DK2079482T3 (de)
ES (1) ES2361696T3 (de)
FR (1) FR2907341B1 (de)
HK (1) HK1132904A1 (de)
HR (1) HRP20110374T1 (de)
IL (1) IL198043A (de)
MA (1) MA30777B1 (de)
MX (1) MX2009003039A (de)
NO (1) NO20091919L (de)
NZ (1) NZ575781A (de)
PL (1) PL2079482T3 (de)
PT (1) PT2079482E (de)
RS (1) RS51729B (de)
RU (1) RU2464041C2 (de)
SI (1) SI2079482T1 (de)
TN (1) TN2009000144A1 (de)
UA (1) UA99601C2 (de)
WO (1) WO2008049990A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2873699B1 (fr) * 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
FR2907341B1 (fr) * 2006-10-18 2012-08-17 Pf Medicament Utilisation d'un anticorps anti-cd151 pour le traitement du cancer
FR2929946B1 (fr) * 2008-04-11 2010-05-28 Pf Medicament Nouveaux anticorps anti-cd151 et leur utilisation pour le traitement du cancer
EP2308897A1 (de) * 2009-10-09 2011-04-13 Pierre Fabre Medicament Chimäre Antikörper spezifisch für CD151 und deren Verwendung zur Behandlung von Krebs
EP2371863A1 (de) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Menschlische Antikörper gegen CXCR4 zur Behandlung von Krebs
WO2012131680A2 (en) 2011-03-28 2012-10-04 Yeda Research And Development Co. Ltd. Compositions and methods for treating inflammation
CN102605057A (zh) * 2012-02-28 2012-07-25 芮屈生物技术（上海）有限公司 癌症病变前期CD151的mRNA水平原位杂交检测试剂盒及检测方法和应用
US9982057B2 (en) 2014-11-17 2018-05-29 Pelican Therapeutics, Inc. Human TNFRSF25 antibody
AU2017278192A1 (en) 2016-06-09 2018-12-13 Pelican Therapeutics, Inc. Anti-TNFRSF25 antibodies
JP7305549B2 (ja) * 2017-04-05 2023-07-10 エックスディーシーエクスプローラー （シャンハイ） カンパニー リミテッド ヒト化抗ｔｐｂｇ抗体およびその製造方法、その複合体および使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
AU4441799A (en) * 1998-06-15 2000-01-05 Research Foundation Of The State University Of New York, The Monoclonal antibodies that recognize antigens associated with tumor metastasis
JP2003189851A (ja) * 2001-12-28 2003-07-08 Japan Science & Technology Corp 抗ヒトｃｄ１５１モノクローナル抗体産生ハイブリドーマ
JP2003321494A (ja) 2002-02-26 2003-11-11 Daiichi Fine Chemical Co Ltd プロｍｍｐ−７の活性化調節方法
EP2041175A4 (de) * 2006-06-23 2011-03-16 Augmenta Biolog Llc Gezielte immunkonjugate
FR2907341B1 (fr) * 2006-10-18 2012-08-17 Pf Medicament Utilisation d'un anticorps anti-cd151 pour le traitement du cancer
FR2929946B1 (fr) * 2008-04-11 2010-05-28 Pf Medicament Nouveaux anticorps anti-cd151 et leur utilisation pour le traitement du cancer

Also Published As

Publication number Publication date
JP5757646B2 (ja) 2015-07-29
US8178096B2 (en) 2012-05-15
WO2008049990A2 (fr) 2008-05-02
WO2008049990A3 (fr) 2008-09-12
MA30777B1 (fr) 2009-10-01
CA2665912C (fr) 2014-12-09
CA2665912A1 (fr) 2008-05-02
IL198043A0 (en) 2011-08-01
ES2361696T3 (es) 2011-06-21
FR2907341A1 (fr) 2008-04-25
PL2079482T3 (pl) 2011-07-29
TN2009000144A1 (fr) 2010-10-18
JP5723420B2 (ja) 2015-05-27
BRPI0717455A2 (pt) 2013-12-24
CN101528256A (zh) 2009-09-09
RS51729B (en) 2011-10-31
HRP20110374T1 (hr) 2011-06-30
ATE499387T1 (de) 2011-03-15
IL198043A (en) 2015-03-31
US20120219569A1 (en) 2012-08-30
CN101528256B (zh) 2013-10-02
KR20090067219A (ko) 2009-06-24
SI2079482T1 (sl) 2011-07-29
UA99601C2 (ru) 2012-09-10
EP2079482A2 (de) 2009-07-22
DK2079482T3 (da) 2011-06-14
JP2013253084A (ja) 2013-12-19
AU2007310763A1 (en) 2008-05-02
NZ575781A (en) 2012-06-29
PT2079482E (pt) 2011-05-25
NO20091919L (no) 2009-05-18
FR2907341B1 (fr) 2012-08-17
US20090324600A1 (en) 2009-12-31
JP2010506888A (ja) 2010-03-04
KR101521863B1 (ko) 2015-05-20
RU2009118440A (ru) 2010-11-27
AU2007310763B2 (en) 2011-02-17
RU2464041C2 (ru) 2012-10-20
EP2079482B1 (de) 2011-02-23
HK1132904A1 (en) 2010-03-12
MX2009003039A (es) 2009-04-02

Similar Documents

Publication Publication Date Title
DE602007012743D1 (de) Verwendung eines antikörpers gegen cd151 bei der behandlung von primären krebs
WO2010019702A3 (en) Ddr1-binding agents and methods of use thereof
NO20085422L (no) Bindingsproteiner for hepatocyttvekstfaktor (HGF)
NO20085421L (no) Bindingsproteiner for hepatocyttvekstfaktor (HGF)
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
CL2008000020A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas sustituidas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y tumores malignos.
WO2014012007A3 (en) Rspo3 binding agents and uses thereof
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
UA108193C2 (uk) Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
MX2009005597A (es) Miembros de enlace para interleucina 6.
EP3103476A3 (de) Antikörper gegen einen proliferationsinduzierenden liganden (april)
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
UA99602C2 (ru) Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток
WO2005090406A3 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
WO2008112290A3 (en) Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer
DE602005025459D1 (de) Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
DE602007009204D1 (de) Von kollagen typ iv abgeleitetes cyclopeptid mit antikrebswirkung
UA107655C2 (uk) Селективні інгібітори антиапоптичних білків bcl-2 для лікування раку і імунних захворювань
UA98756C2 (ru) Антитело, которое связывается с cd38, для лечения заболевания, опосредованного cd38
EA202090198A1 (ru) Комбинированное лечение опухолей, экспрессирующих cd38